KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovoCure (NVCR) Tax Provisions (2016 - 2025)

Historic Tax Provisions for NovoCure (NVCR) over the last 12 years, with Q3 2025 value amounting to $7.2 million.

  • NovoCure's Tax Provisions fell 1933.22% to $7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.1 million, marking a year-over-year decrease of 2308.04%. This contributed to the annual value of $37.5 million for FY2024, which is 14482.13% up from last year.
  • Per NovoCure's latest filing, its Tax Provisions stood at $7.2 million for Q3 2025, which was down 1933.22% from $5.2 million recorded in Q2 2025.
  • NovoCure's 5-year Tax Provisions high stood at $10.7 million for Q4 2024, and its period low was $652000.0 during Q2 2022.
  • Moreover, its 5-year median value for Tax Provisions was $3.5 million (2023), whereas its average is $4.5 million.
  • Per our database at Business Quant, NovoCure's Tax Provisions crashed by 7735.41% in 2021 and then skyrocketed by 61140.14% in 2024.
  • Over the past 5 years, NovoCure's Tax Provisions (Quarter) stood at $885000.0 in 2021, then surged by 436.16% to $4.7 million in 2022, then skyrocketed by 80.08% to $8.5 million in 2023, then rose by 25.41% to $10.7 million in 2024, then plummeted by 32.36% to $7.2 million in 2025.
  • Its Tax Provisions stands at $7.2 million for Q3 2025, versus $5.2 million for Q2 2025 and $4.0 million for Q1 2025.